Comparison of Splenectomy and Eltrombopag Treatment in the Second-Line Treatment of Immune Thrombocytopenic Purpura

Overview

Journal Turk J Haematol

Specialty Hematology

Date 2021 Jun 24

PMID 34162173

Authors

Mehmet Can Ugur

Sinem Namdaroglu

Esma Evrim Dogan

Esra Turan Erkek

Nihan Nizam

Rafet Eren

Oktay Bilgir

Affiliations

Soon will be listed here.

Abstract

Objective: Primary immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by isolated thrombocytopenia. While first-line treatments focus on inhibiting autoantibodies and platelet destruction, second- and third-line treatments include splenectomy and thrombopoietin receptor agonists. In this study, we aimed to compare the efficiency and toxicities of splenectomy and eltrombopag as second-line treatments in ITP.

Materials And Methods: We retrospectively analyzed patients who were diagnosed with ITP and followed between 2015 and 2020. Patients who underwent splenectomy or received eltrombopag treatment as second-line or further therapy were included. For subgroup analyses, patients were further stratified according to whether they received eltrombopag in the second or third line of treatment.

Results: There were 38 patients in the splenectomy group and 47 patients in the eltrombopag group. The mean age of patients in the splenectomy and eltrombopag groups was 43.2 and 50.5 years, respectively. Time to response was significantly shorter in the splenectomy arm (p=0.001). However, response rates at the 3, 6, 12, and 24 months did not exhibit a statistically significant difference between groups; nor did total duration of response and adverse events. Response rates at the 1, 3, 6, 12, and 24 months and the total duration of response did not exhibit a statistically significant difference between eltrombopag subgroups. Eltrombopag treatment was ceased for 20 patients after a median of 54.1 months (range: 1-151). Among them, 12 patients (60%) did not experience a loss of response.

Conclusion: Comparing the splenectomy and eltrombopag arms, even though time to achieve response was in favor of the splenectomy group, this advantage disappeared when overall response rates and response rate at the 2 year were considered. Using eltrombopag in the second or third line of therapy does not yield any difference in terms of time to achieving response.

References

Cheng G, Saleh M, Marcher C, Vasey S, Mayer B, Aivado M . Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2010; 377(9763):393-402. DOI: 10.1016/S0140-6736(10)60959-2. View

Thomsen R, Schoonen W, Farkas D, Riis A, Jacobsen J, Fryzek J . Risk for hospital contact with infection in patients with splenectomy: a population-based cohort study. Ann Intern Med. 2009; 151(8):546-55. DOI: 10.7326/0003-4819-151-8-200910200-00008. View

Wong R, Saleh M, Khelif A, Salama A, Portella M, Burgess P . Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017; 130(23):2527-2536. DOI: 10.1182/blood-2017-04-748707. View

Mishra K, Pramanik S, Jandial A, Sahu K, Sandal R, Ahuja A . Real-world experience of eltrombopag in immune thrombocytopenia. Am J Blood Res. 2020; 10(5):240-251. PMC: 7675127. View

Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold D . Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2008; 113(11):2386-93. DOI: 10.1182/blood-2008-07-162503. View

Gigot J, Healy M, Ferrant A, Michaux J, Njinou B, Kestens P . Laparoscopic splenectomy for idiopathic thrombocytopenic purpura. Br J Surg. 1994; 81(8):1171-2. DOI: 10.1002/bjs.1800810830. View

Gonzalez-Lopez T, Alvarez-Roman M, Pascual C, Sanchez-Gonzalez B, Fernandez-Fuentes F, Jarque I . Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice. Eur J Haematol. 2015; 97(3):297-302. DOI: 10.1111/ejh.12725. View

Olsson B, Andersson P, Jernas M, Jacobsson S, Carlsson B, Carlsson L . T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003; 9(9):1123-4. DOI: 10.1038/nm921. View

Roark J, Bussel J, Cines D, Siegel D . Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood. 2002; 100(4):1388-98. View

10.

Ozdemirkiran F, Payzin B, Kiper H, Kabukcu S, Akgun Cagliyan G, Kahraman S . Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience. Turk J Haematol. 2015; 32(4):323-8. PMC: 4805331. DOI: 10.4274/tjh.2014.0152. View

11.

Provan D, Arnold D, Bussel J, Chong B, Cooper N, Gernsheimer T . Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019; 3(22):3780-3817. PMC: 6880896. DOI: 10.1182/bloodadvances.2019000812. View

12.

Chaturvedi S, Arnold D, McCrae K . Splenectomy for immune thrombocytopenia: down but not out. Blood. 2018; 131(11):1172-1182. PMC: 5855018. DOI: 10.1182/blood-2017-09-742353. View

13.

Bussel J, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L . Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 373(9664):641-8. DOI: 10.1016/S0140-6736(09)60402-5. View

14.

Tastaldi L, Krpata D, Prabhu A, Petro C, Haskins I, Perez A . Laparoscopic splenectomy for immune thrombocytopenia (ITP): long-term outcomes of a modern cohort. Surg Endosc. 2018; 33(2):475-485. DOI: 10.1007/s00464-018-6321-y. View

15.

Broudy V, Lin N . AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine. 2003; 25(2):52-60. DOI: 10.1016/j.cyto.2003.05.001. View

16.

Erickson-Miller C, Delorme E, Tian S, Hopson C, Landis A, Valoret E . Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2008; 27(2):424-30. PMC: 2729672. DOI: 10.1634/stemcells.2008-0366. View

17.

Khodadi E, Asnafi A, Shahrabi S, Shahjahani M, Saki N . Bone marrow niche in immune thrombocytopenia: a focus on megakaryopoiesis. Ann Hematol. 2016; 95(11):1765-76. DOI: 10.1007/s00277-016-2703-1. View

18.

Bisharat N, Omari H, Lavi I, Raz R . Risk of infection and death among post-splenectomy patients. J Infect. 2002; 43(3):182-6. DOI: 10.1053/jinf.2001.0904. View

19.

Salib M, Clayden R, Clare R, Wang G, Warkentin T, Crowther M . Difficulties in establishing the diagnosis of immune thrombocytopenia: An agreement study. Am J Hematol. 2016; 91(8):E327-9. DOI: 10.1002/ajh.24404. View

20.

Bylsma L, Fryzek J, Cetin K, Callaghan F, Bezold C, Mehta B . Systematic literature review of treatments used for adult immune thrombocytopenia in the second-line setting. Am J Hematol. 2018; 94(1):118-132. PMC: 6587722. DOI: 10.1002/ajh.25301. View